RT Journal Article
SR Electronic
T1 Segregation analysis of 17,425 population-based breast cancer families: evidence for genetic susceptibility and risk prediction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.24.22275555
DO 10.1101/2022.05.24.22275555
A1 Li, Shuai
A1 MacInnis, Robert J.
A1 Lee, Andrew
A1 Nguyen-Dumont, Tu
A1 Dorling, Leila
A1 Carvalho, Sara
A1 Dite, Gillian S.
A1 Shah, Mitul
A1 Luccarini, Craig
A1 Wang, Qin
A1 Milne, Roger L.
A1 Jenkins, Mark A.
A1 Giles, Graham G.
A1 Dunning, Alison M.
A1 Pharoah, Paul D.P.
A1 Southey, Melissa C.
A1 Easton, Douglas F.
A1 Hopper, John L.
A1 Antoniou, Antonis C.
YR 2022
UL http://medrxiv.org/content/early/2022/05/25/2022.05.24.22275555.abstract
AB Rare pathogenic variants in known breast cancer susceptibility genes and known common susceptibility variants do not fully explain the familial aggregation of breast cancer. To investigate plausible genetic models for the residual familial aggregation, we studied 17,425 families ascertained through population-based probands, 86% of whom were screened for pathogenic variants in BRCA1, BRCA2, PALB2, CHEK2, ATM and TP53 using gene-panel sequencing. We conducted complex segregation analyses and fitted genetic models in which breast cancer incidence depended on the effects of pathogenic variants in known susceptibility genes and other unidentified major genes, and a normally distributed polygenic component. The proportion of familial variance explained by BRCA1, BRCA2, PALB2, CHEK2, ATM and TP53 was 46% at age 20-29 years and decreased steadily with age thereafter. After allowing for these genes, the best fitting model for the residual familial variance included a recessively inherited risk component with a combined genotype frequency of 1.7% (95% CI: 0.3-5.4%) and a penetrance to age 80 years of 69% (95% CI: 38-95%) for homozygotes, and a polygenic variance of 1.27 (95% CI: 0.94-1.65) which did not vary with age. The proportion of the residual familial variance explained by the recessive risk component was 40% at age 20-29 years and decreased with age thereafter. The model predicted age-specific familial relative risks consistent with those observed by large epidemiological studies. The findings have implications for strategies to identify new breast cancer susceptibility genes and improve breast cancer risk prediction, especially at a young age.Competing Interest StatementA.C.A., A.L. and D.F.E. are listed as creators of BOADICEA v.5 which has been licensed by Cambridge Enterprise. G.D.S is an employee of Genetic Technologies Ltd. The other authors have no conflict of interest to declare.Funding StatementWe thank all the participants in this study, the entire team of the ABCFR and past and current investigators. The work was supported by Cancer Research UK grant PPRPGM-Nov20\100002, NIHR Cambridge Biomedical Research Centre, Victorian Cancer Agency grant ECRF19020, Picchi Award for Excellence in Cancer Research from the Victorian Comprehensive Cancer Centre and the U.S. National Institute of Health (grant number RO1CA159868). The ABCFR was supported in Australia by the National Health and Medical Research Council (NHMRC), the New South Wales Cancer Council, the Victorian Health Promotion Foundation, the Victorian Breast Cancer Research Consortium, Cancer Australia, and the National Breast Cancer Foundation. The six sites of the Breast Cancer Family Registry (BCFR) were supported by grant UM1 CA164920 from the U.S. National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the BCFR. Sequencing of the ABCFR samples was supported by an NHMRC Program grant (APP1074383), The National Breast Cancer Foundation (BRA-STRAP; NT-15-016), NHMRC European Union Collaborative Research Grant (APP1101400) and Monash University, Melbourne, Australia. SEARCH was funded by Cancer Research UK (C490/A16561) and the NIHR Biomedical Research Centre at the University of Cambridge and the University of Cambridge has received salary support for P.D.P.P. from the NHS in the East of England through the Clinical Academic Reserve. Sequencing of the SEARCH samples was funded by European Union's Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935). S.L. is a Victorian Cancer Agency (VCA) Early Career Research Fellow (ECRF19020). TN-D is a VCA Mid-Career Research Fellow (MCRF21029). M.C.S. is an NHMRC Senior Research Fellow (APP1155163). J.L.H. is an NHMRC Senior Principal Research Fellow.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Australian Breast Cancer Family Registry (ABCFR) was approved by the Human Research Ethics Committee of the University of Melbourne. Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) was approved by the National Research Ethics Service Committee East of England Cambridge South. All participants provided written consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for access to the data analysed in this study should be made to J.L.H. (ABCFR) and P.D.P. (SEARCH).